Antagonists of MCP-1 function and methods of use thereof
US6992086B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2003 |
| Grant date | Jan 31, 2006 |
| Priority date | — |
| Expiry date | Nov 17, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.